Standout Papers

Idarucizumab for Dabigatran Reversal 2015 2026 2018 2022 964
  1. Idarucizumab for Dabigatran Reversal (2015)
    Charles V. Pollack, Paul A. Reilly et al. New England Journal of Medicine
  2. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial (2015)
    Jean‐Charles Soria, Enriqueta Felip et al. The Lancet Oncology

Immediate Impact

5 from Science/Nature 63 standout
Sub-graph 1 of 19

Citing Papers

Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
Reteplase versus Alteplase for Acute Ischemic Stroke
2024 Standout
5 intermediate papers

Works of Bushi Wang being referenced

Idarucizumab for Dabigatran Reversal
2015 Standout
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
2015 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Bushi Wang 557 670 25 889 643 24 1.9k
J P Boissel 408 484 39 706 597 42 2.1k
Xiaolei Zhu 816 656 9 612 231 34 2.0k
Julie Hambleton 1127 591 17 645 652 31 3.0k
Gregory C. Connolly 376 165 672 1206 31 1.7k
Sanjeev Francis 198 212 4 917 255 44 2.5k
Jean Marc Extra 846 207 13 434 578 21 1.6k
Ann Alexis Prestrud 667 302 8 343 469 17 2.4k
Rainer Vormittag 390 234 3 932 1708 37 2.4k
Gyongyi Nadasdy 455 318 506 252 49 2.9k
Roger Keresztes 1078 618 10 286 240 36 2.6k

All Works

Loading papers...

Rankless by CCL
2026